felin
infecti
periton
viru
fipv
coronaviru
induc
fatal
system
diseas
mediat
inappropri
immun
respons
previou
vaccin
attempt
fipv
unsuccess
igg
antibodi
surfac
protein
enhanc
infect
howev
two
studi
shown
poxviru
vector
vaccinia
wr
canarypox
express
fipv
membran
protein
elicit
partial
protect
immun
suppos
cellmedi
virolog
intern
patent
wo
studi
report
construct
anoth
poxviru
modifi
vaccinia
viru
ankara
mva
express
vector
fipv
protein
vector
gene
insert
downstream
strong
earlyl
promot
wherea
two
previous
describ
poxvirus
express
protein
earli
stage
immunogen
recombin
mvam
evalu
murin
model
reveal
effect
vector
balanc
vaccin
test
cat
evalu
efficaci
fipv
challeng
vaccin
kitten
develop
fipvspecif
antibodi
immun
howev
none
protect
fipv
result
suggest
crucial
role
type
poxvir
promot
must
use
induc
effect
immun
respons
fipv
felin
coronavirus
fcov
caus
either
mild
enterit
diseas
fatal
periton
cat
thu
classifi
two
group
depend
pathogen
felin
enterit
coronavirus
fecv
felin
infecti
periton
virus
fipv
see
review
olsen
sever
vaccin
trial
lethal
fipv
strain
attempt
often
unsuccess
due
problem
antibodydepend
enhanc
ade
diseas
lead
earli
death
contrast
cat
natur
resist
fipv
present
strong
cellmedi
immun
cmi
weak
antibodi
respons
pedersen
therefor
effici
vaccin
preferenti
induc
cmi
also
call
respons
character
helper
tlymphocyt
secret
interleukin
interferon
gamma
ifn
cell
cytotox
tlymphocyt
ctl
fipv
virion
contain
three
major
structur
protein
kda
spike
glycoprotein
kda
membran
protein
kda
nucleoprotein
n
protein
shown
respons
ade
thu
induc
protect
immun
respons
vennema
et
al
contrast
protein
n
protein
partial
protect
express
poxviru
vector
like
vaccinia
canarypox
virus
paoletti
gettig
vennema
et
al
protect
occur
absenc
neutral
antibodi
thought
due
cmi
canarypox
vacciniabas
vaccin
express
protein
earli
stage
viral
cycl
canarypox
achiev
late
stage
mammalian
cell
gene
insert
downstream
earli
promot
vaccinia
studi
report
use
anoth
poxviru
vector
modifi
vaccinia
viru
ankara
mva
recent
show
promis
result
vaccin
simianhuman
immunodefici
viru
amara
et
al
mva
attenu
strain
vaccinia
viru
ankara
lost
abil
replic
mammalian
cell
sutter
moss
thu
mva
safe
remain
strong
express
vector
still
express
foreign
antigen
earli
late
stage
life
cycl
herein
use
featur
construct
recombin
mva
express
protein
mvam
stage
order
synthes
larger
amount
antigen
compar
canarypoxm
vacciniam
vaccin
immunogen
enhanc
express
vector
test
vivo
preliminari
trial
murin
model
show
effect
mva
balanc
data
taken
account
design
cat
trial
anim
challeng
virul
fipv
strain
pedersen
et
al
evalu
efficaci
mvam
vaccin
mva
kindli
provid
b
moss
nih
recombin
mva
cultur
primari
chicken
embryo
fibroblast
cef
eagl
minimum
essenti
medium
mem
gibco
brl
supplement
fetal
calf
serum
fc
vaccin
studi
virus
purifi
infect
cell
lysat
centrifug
g
hour
minut
beckman
rotor
sucros
cushion
fipv
strain
kindli
given
n
pedersen
propag
feli
catu
whole
cell
dulbecco
modifi
eagl
medium
dmem
gibco
brl
fc
viruscontain
cultur
supernat
use
cat
challeng
titrat
elisa
antigen
splenocyt
stimul
cell
cultur
supernat
inactiv
propionolacton
centrifug
g
pellet
viru
resuspend
phosphat
buffer
salin
pb
store
vrm
plasmid
contain
gene
cdna
fipv
kindli
given
veterinari
univers
utrecht
vennema
et
al
gene
isol
digest
vrm
bamhi
hincii
insert
bamhi
hincii
treat
plasmid
obtain
nih
wyatt
et
al
contain
modifi
earlyl
promot
gene
vaccinia
viru
two
flank
target
recombin
delet
iii
mva
genom
recombin
perform
describ
elsewher
modif
wyatt
et
al
briefli
monolay
nearli
confluent
cef
infect
mva
multipl
plaqueform
unit
pfu
per
cell
transfect
hour
per
mm
well
use
dotap
roch
cell
harvest
hour
later
lyse
freezingthaw
sonic
recombin
virus
express
protein
detect
immunostain
infect
cef
ascit
fipv
infect
cat
specif
antibodi
reveal
peroxidas
conjug
anticat
igg
jackson
carbazol
substrat
six
success
plaqu
purif
stock
prepar
cef
titrat
mvam
stock
perform
doubl
stain
ascit
fipvinfect
cat
rabbit
antivaccinia
antibodi
jackson
cef
infect
mvam
wild
type
mva
multipl
pfucel
twentyfour
hour
later
supernat
centrifug
g
hour
beckman
optima
tl
centrifug
rotor
tla
order
harvest
cell
debri
contain
protein
pellet
load
nupag
gel
novex
analyz
western
blot
use
two
monoclon
antibodi
specif
fipv
mprotein
precis
antibodi
made
laboratori
follow
alkalin
phosphataseconjug
antimous
igg
southern
biotechnolog
associ
nitrobluetetrazolium
phosphat
nbtbcip
sigma
use
phosphatas
substrat
studi
carri
femal
balbc
mice
iffa
credo
franc
anim
specif
pathogen
free
spf
group
five
mice
vaccin
subcutan
vaccin
contain
pfu
purifi
mva
mvam
phosphat
buffer
salin
pb
blood
sampl
retroorbit
plexu
spleen
collect
either
two
four
week
last
immun
fifteen
specif
pathogen
free
european
femal
kitten
purchas
harlan
us
anim
age
eight
nine
week
begin
experi
two
group
five
cat
immun
subcutan
one
inject
week
experi
two
inject
week
week
pfu
recombin
mvam
ml
pb
five
control
cat
nonvaccin
six
week
begin
studi
cat
inocul
oronas
tcid
fipv
ml
dmem
fc
blood
sampl
collect
anim
anaesthet
tiletamin
zolazepam
zoletil
virbac
vaccin
challeng
time
order
analyz
fipvspecif
serolog
clinic
sign
anorexia
icteru
anemia
prostrat
periton
swell
monitor
daili
hematolog
paramet
analyz
weekli
anim
sacrif
six
week
challeng
day
deem
moribund
antigenspecif
igg
antibodi
quantifi
enzymelink
immunosorb
assay
elisa
briefli
microtit
plate
dynex
immulon
coat
purifi
fipv
concentr
carbon
buffer
incub
overnight
well
wash
pb
tween
satur
bsa
hour
wash
threefold
serial
dilut
cat
sera
mous
sera
incub
well
hour
fipvspecif
murin
igg
detect
appropri
peroxidaseconjug
goat
antimous
antibodi
southern
biotechnolog
associ
dilut
tne
bsa
hour
detect
felin
igg
peroxidaseconjug
sheep
anticat
igg
cappel
organon
teknika
dilut
plate
wash
five
time
bound
peroxidas
activ
reveal
azinobi
acid
abt
minut
room
temperatur
absorb
measur
nm
antibodi
titer
defin
higher
serum
dilut
absorb
greater
three
time
blank
valu
spleen
mice
group
pool
crush
syring
mononuclear
white
cell
isol
centrifug
ficol
g
minut
jouan
recov
splenocyt
stimul
hour
rpmi
medium
complement
fc
iuml
penicillin
streptomycin
gibco
inactiv
fipv
concanavalin
sigma
posit
control
total
rna
splenocyt
extract
rneasi
midi
kit
qiagen
accord
manufactur
procedur
treat
rnasefre
dnase
mrna
revers
transcrib
cdna
superscript
preamplif
system
gibco
brl
oligodt
primer
five
microlit
cdna
use
per
reaction
cytokin
multiplex
pcr
assay
biosourc
mous
set
accord
manufactur
protocol
pcr
product
separ
agaros
gel
fipv
gene
insert
delet
iii
mva
genom
homolog
recombin
recombin
mvam
stabl
replic
high
titer
cef
express
protein
cef
infect
mvam
visual
western
blot
use
two
appropri
monoclon
antibodi
doubl
band
approxim
kda
detect
mvaminfect
cef
cultur
supernat
mva
control
fig
two
band
correspond
glycosyl
unglycosyl
form
protein
sinc
tunicamycin
treatment
result
disappear
upper
form
data
shown
preliminari
studi
immunogen
mvam
evalu
murin
model
mice
subcutan
vaccin
one
two
dose
pfu
mvam
addit
want
check
antivector
immun
could
inhibit
vaccin
uptak
therefor
one
group
naiv
mice
preimmun
pfu
wild
type
mva
wtmva
vaccin
pfu
mvam
two
four
week
later
product
differ
igg
isotyp
compar
naiv
mice
inocul
twice
pfu
mvam
mice
immun
mvam
contruct
develop
strong
fipvspecif
humor
respons
titer
greater
pool
sera
mice
preimmun
wtmva
pool
sera
naiv
mice
receiv
one
inject
mvam
gave
igg
titer
indic
preimmun
vector
abl
inhibit
protein
express
recombin
viru
fig
b
howev
analysi
igg
subclass
show
import
differ
among
three
group
naiv
mice
immun
mvam
develop
low
respons
high
titer
suggest
predomin
activ
lymphocyt
mice
immun
twice
viru
produc
significantli
higher
titer
newmankeul
multiplecomparison
test
surprisingli
mice
preimmun
wtmva
produc
predominantli
fipvspecif
inocul
pfu
mvam
equival
doubl
inject
weaker
level
signific
differ
accord
newmankeul
multiplecomparison
test
invers
ratio
observ
two
inject
either
two
four
week
interv
fig
b
confirm
observ
cytokin
mrna
pattern
analyz
qualit
multiplex
rtpcr
assay
order
determin
profil
experi
carri
total
rna
extract
splenocyt
vitro
restimul
fipv
result
show
presenc
ifn
type
cytokin
also
type
cytokin
mrna
spleen
cell
naiv
mice
vaccin
twice
mvam
fig
data
indic
mix
respons
anim
correl
product
antibodi
respect
furthermor
band
correspond
intens
anim
receiv
two
inject
mvam
give
good
correl
high
titer
mice
preimmun
wtmva
show
cytokin
pattern
presenc
slight
band
except
ifnwhich
surprisingli
undetect
reveal
inhibit
lymphocyt
conclus
two
group
present
high
level
fipvspecif
rais
either
strong
respons
demonstr
cytokin
two
mvam
inject
moder
respons
accompani
inhibit
ifn
secret
cell
wtmva
mvam
immun
latter
case
lack
ifnwa
correl
low
titer
mvam
vaccin
test
felin
model
order
valid
protect
effect
protein
investig
efficaci
new
vector
cat
immun
follow
onestep
twostep
schedul
pfu
per
anim
subsequ
oronas
challeng
tcid
fipv
challeng
dose
defin
fipv
titer
induc
fip
clinic
sign
unvaccin
kitten
preliminari
trial
unpublish
data
cat
bled
vaccin
challeng
time
one
week
follow
fipv
challeng
coronaviru
serolog
monitor
fig
singl
mvam
inocul
week
vaccin
anim
develop
fipvspecif
igg
humor
respons
homogen
within
vaccin
group
boost
second
inject
reach
titer
one
week
fipv
challeng
cat
vaccin
twice
mvam
show
increas
coronavirusspecif
igg
control
cat
start
develop
specif
humor
respons
one
week
postinfect
kitten
show
sever
drop
lymphocyt
count
data
shown
lymphopenia
persist
six
week
follow
challeng
signific
differ
two
vaccin
group
control
group
similarli
cat
vaccin
present
strong
anemia
first
week
infect
everi
cat
group
present
fip
symptom
week
postinfect
lead
death
euthanasia
week
shown
mortal
curv
fig
correl
serolog
statu
evolut
diseas
aim
studi
evalu
poxviru
mva
vaccin
fipv
first
gene
insert
mva
genom
homolog
recombin
downstream
earlyl
promot
mvam
inject
mice
cat
order
evalu
immunogen
efficaci
either
one
two
inject
pfu
observ
mvam
vector
induc
strong
fipvspecif
igg
respons
result
indic
mvam
express
fipv
protein
vivo
immunogen
one
drawback
use
recombin
viru
immun
respons
direct
vector
may
preclud
express
gene
interest
gain
inform
point
group
mice
first
prime
mva
vaccin
mvam
observ
mvaimmun
mice
develop
mvam
boost
fipvspecif
antibodi
titer
equal
naiv
mice
singl
mvam
inject
data
support
idea
vector
neutral
accord
report
recombin
mva
express
env
gene
ramirez
et
al
surprisingli
mode
vaccin
modifi
helper
statu
respons
sinc
mvaprim
mice
clearli
show
respons
fipv
evidenc
predomin
antim
antibodi
mrna
express
splenocyt
strike
effect
ifnwa
longer
detect
rtpcr
wtmvaprim
mice
wherea
cytokin
express
vaccin
naiv
mice
result
confirm
ramirez
et
al
report
decreas
ifn
secret
cell
mice
prime
mva
boost
mvaenv
ramirez
et
al
thu
observ
indic
mva
abl
induc
environ
henc
predispos
immun
system
rais
respons
coexpress
antigen
experi
also
indic
onset
immun
memori
evidenc
increas
lymphocyt
four
week
prime
observ
suggest
mva
creat
transient
environ
also
gener
memori
cell
antigen
act
helper
signal
subsequ
immun
alreadi
report
increas
dose
mva
elicit
cell
differenti
ramirez
et
al
show
iter
inject
mvam
especi
preexist
immun
poxviru
also
modul
immun
respons
phenomenon
clear
explan
well
known
poxvirus
possess
factor
like
virokin
escap
immun
system
kotwal
factor
may
contribut
reorient
immun
respons
howev
mva
lost
major
sequenc
except
receptor
solubl
receptor
antoin
et
al
smith
et
al
latter
could
influenc
decreas
activ
cell
sinc
act
synergi
promot
ifnsecret
okamura
et
al
interfer
could
provid
one
explan
emerg
environ
especi
inhibit
ifnexpress
consequ
poxviru
prime
despit
induct
fig
type
hypothesi
confirm
experi
includ
receptordelet
mva
find
may
import
implic
especi
vaccin
fipv
inde
fipv
infect
may
constrain
strong
cellmedi
immun
wherea
immun
seem
correl
patholog
murin
model
inform
protect
effect
fipv
vaccin
mvam
evalu
cat
trial
two
protocol
deduc
mice
experi
one
hand
singl
inject
induc
respons
seem
promis
control
fipv
hand
twostep
immun
elicit
mix
immun
effect
sinc
similar
vaccin
schedul
partial
protect
replic
vaccinia
viru
western
reserv
strain
vennema
et
al
nonrepl
canarypox
viru
paoletti
gettig
mva
shown
potent
express
vector
vaccinia
wr
term
immun
respons
induct
ramirez
et
al
probabl
replicationdefect
mammal
lost
sever
virul
factor
furthermor
mva
still
produc
antigen
interest
earli
late
stage
poxviru
cycl
like
vaccinia
unlik
canarypox
express
earli
gene
mammal
sutter
moss
therefor
expect
protect
effect
protein
could
enhanc
mva
context
compar
vaccinia
canarypox
vector
cat
immun
twice
pfu
recombin
mvam
anim
develop
coronavirusspecif
antibodi
demonstr
effect
vector
howev
despit
induct
rel
high
igg
respons
titer
anim
vaccin
twice
none
vaccin
cat
surviv
lethal
fipv
challeng
murin
model
observ
number
mvam
inject
influenc
balanc
howev
cat
trial
term
protect
differ
observ
two
vaccin
group
similar
assay
vaccinia
viru
wr
express
antigen
canarypoxm
partial
protect
fipv
strain
lack
efficaci
mvam
might
explain
differ
promot
construct
vaccinia
wr
canarypox
gene
express
restrict
earli
stage
viral
cycl
mva
gene
control
modifi
promot
enabl
strong
express
earli
late
stage
viral
cycl
earli
express
antigen
poxviru
known
induc
cellmedi
immun
wherea
late
express
favor
humor
immun
bront
et
al
thu
late
express
protein
mvam
explain
high
fipvspecif
igg
respons
antibodi
may
contribut
patholog
fipv
immunemedi
diseas
although
mspecif
antibodi
enhanc
viru
entri
macrophag
might
involv
format
immun
complex
exampl
conclus
studi
demonstr
protocol
immun
mvam
construct
protect
fipv
challeng
kitten
probabl
strong
induct
fipvspecif
antibodi
type
poxvir
promot
seem
crucial
import
minim
humor
respons
elicit
effici
cellmedi
immun
type
immun
may
enhanc
dna
vaccin
prime
seen
studi
ramshaw
ramsay
furthermor
protein
appar
suffici
induc
protect
immun
associ
fipv
antigen
still
determin
